Depakote
Product Images NDC 0074-7126

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Depakote (NDC 0074-7126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Is A Stable Co-ordination Compound Comprised Of Sodium Valproate And Valproic Acid In A 1:1 Molar Relationship And Formed During The Partial Neutralization Of Valproic Acid With 0.5 Equivalent Of Sodium Hydroxide. Chemically It Is Designated As Sodium Hydrogen Bis(2-propylpentanoate). Divalproex Sodium Has The Following Structure: (Depakote Er Spl 01)

Chemical structure of valproate, the active ingredient in Depakote ER. The diagram features the valproate ion with associated sodium ion and organic groups shown in a structural formula.*

FDA Label Image

Figure 1 (Depakote Er Spl 02)

A cumulative distribution plot showing percentage reduction in CPS rate for patients on Depakote versus placebo. The x-axis represents the percent of patients, and the y-axis shows percent reduction in CPS rate with improvement upward and worsening downward. Depakote demonstrates a greater percentage of patients with improvement compared to placebo.*

FDA Label Image

Figure 2 (Depakote Er Spl 03)

A line graph comparing High Dose and Low Dose Depakote showing percent reduction in CPS (clinical parameter scale) rate on the vertical axis against percent of patients on the horizontal axis. The graph illustrates the distribution of patients experiencing improvement, no change, or worsening in CPS rate with Depakote treatment.*

FDA Label Image

Figure 3 (Depakote Er Spl 04)

A bar graph comparing two groups: Placebo (open bar) with a value of 0.6 and Depakote ER (solid black bar) with a value of 1.2. The graph includes a statistical significance marker indicating p=0.006 for the difference between groups.*

FDA Label Image

Ndc 0074-3826-13 100 Tablets Once-daily Dosing Depakote® Er Divalproex Sodium Extended-release Tablets 250 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Er Spl 05)

Label for Depakote ER 250 mg extended-release tablets containing divalproex sodium. The label indicates once-daily dosing for 100 tablets, manufactured by AbbVie Inc. It includes storage instructions and a note that each tablet contains divalproex sodium equivalent to 250 mg valproic acid.*

FDA Label Image

Ndc 0074-7126-11 100 Tablets To Open Tear Back Along Perforation Dispense The Accompanying Medication Guide To Each Patient. Rx Only Once-daily Dosing Depakote® Er Divalproex Sodium Extended-release Tablets 500 mg Valproic Acid Activity Tamper-evident: Do Not Accept If Opened Or Seal Has Been Broken. This Package For Households Without Young Children (Depakote Er Spl 06)

Label for Depakote ER 250 mg extended-release tablets by AbbVie Inc. The label shows the product name, strength (250 mg), active ingredient divalproex sodium, and valproic acid activity. It includes dispensing instructions, storage conditions, and manufacturer information, along with barcodes and a note for prescription use only.*

FDA Label Image

Ndc 0074-7126-13 100 Tablets Once-daily Dosing Depakote® Er Divalproex Sodium Extended-release Tablets 500 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Er Spl 07)

Packaging label for Depakote ER 500 mg extended-release tablets, containing divalproex sodium with valproic acid activity. The label includes branding with Depakote ER in bold letters and specifies a 100-tablet count. Manufactured by AbbVie Inc., the label features barcodes and standard FDA packaging information for prescription use only.*

FDA Label Image

Depakote Er Spl 08

Label for Depakote ER 500 mg extended-release tablets, containing divalproex sodium, provided by AbbVie Inc. The label indicates once-daily dosing and includes a quantity of 100 tablets. It also features storage instructions, a barcode, and manufacturing information from AbbVie Ltd., Barceloneta, PR.*

FDA Label Image

Depakote Er Spl 09

Depakote ER 500 mg extended-release tablets packaging label showing the product name, active ingredient divalproex sodium, and 100 tablets count. The label emphasizes once-daily dosing and valproic acid activity. It includes storage instructions, manufacturer information (AbbVie Inc.), and a barcode with NDC 0074-7402-13.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.